Immuneel Therapeutics Unveils Qartemi: Pioneering CAR-T Cancer Therapy in India

Immuneel Therapeutics has achieved a groundbreaking milestone in Indian healthcare with the launch of Qartemi, the country’s first global CAR T-cell therapy for treating adult B-cell Non-Hodgkin Lymphoma (B-NHL). This revolutionary development signifies a transformative leap in cancer immunotherapy, offering patients access to cutting-edge treatments at a fraction of global costs.

Qartemi: Revolutionizing India’s Cancer Care

Qartemi stands as a beacon of hope for cancer patients in India, particularly those battling relapsed or refractory B-NHL. It offers a new lease on life for individuals who have exhausted conventional treatment options such as chemotherapy.

Why Qartemi is Revolutionary

• Globally Benchmarked: Qartemi meets international standards of safety and efficacy.

• Personalized Therapy: Utilizes a patient’s own immune cells to combat cancer.

• Affordable Access: Developed indigenously at Immuneel's Bengaluru facility, making it accessible to a wider demographic.

Rising Cancer Burden in India

With over 120,000 new blood cancer cases and 70,000 annual deaths from leukaemia, lymphoma, and multiple myeloma, the need for advanced therapies like Qartemi is critical. Immuneel’s innovation directly addresses this challenge, offering a lifeline to thousands of patients each year.

Statements from Visionary Leaders

Kiran Mazumdar-Shaw, Co-Founder of Immuneel Therapeutics

“Since Immuneel’s inception in 2019, our mission has been to offer affordable and innovative lifesaving therapies for cancer that are otherwise inaccessible... Designed to improve patient outcomes, Qartemi exemplifies our commitment to positioning India as a leader in next-generation transformative therapies.”

Siddhartha Mukherjee, Co-Founder of Immuneel Therapeutics

“The launch of Qartemi marks a pivotal moment in India’s fight against cancer. By combining world-class research in CAR T-cell therapy with indigenous manufacturing, we are offering new hope to patients facing aggressive blood cancers.”

Amit Mookim, CEO of Immuneel Therapeutics

“Qartemi is a testament to our unwavering commitment to bringing world-class care closer to home... For the first time, Indian patients now have access to lasting remission of relapsed and refractory Non-Hodgkin Lymphoma.”

The IMAGINE Trial: Proving Efficacy and Safety

Immuneel conducted India’s first CAR T-cell therapy trials in 2022, known as the IMAGINE trial, across leading hospitals like Narayana Hospital, Apollo Cancer Hospital, and PGIMER. Results demonstrated that Qartemi’s safety and efficacy were on par with USFDA-approved CAR T-cell therapies.

Collaborations and Accessibility

To ensure widespread accessibility, Immuneel has partnered with premier healthcare institutions across India, including:

• Narayana Health

• Apollo Hospitals

• CMC Vellore

• Manipal Hospitals

• SGPGI Lucknow

Additionally, CellSpectrum™, a comprehensive platform by Immuneel, supports patients and healthcare professionals with educational resources, clinical insights, and personalized tools to simplify the treatment journey.

Licensed Expertise from Global Leaders

Qartemi leverages expertise licensed from the Hospital Clínic de Barcelona (HCB), a pioneer in cell therapy innovation. This partnership ensures Indian patients receive therapies that are at par with international standards.

The Future of Cancer Therapy in India

Qartemi not only redefines cancer treatment in India but also positions the country as a leader in advanced immunotherapies. With its focus on affordability and accessibility, Immuneel is bridging the gap between cutting-edge science and patient care.

Conclusion: A New Dawn in Cancer Treatment

The launch of Qartemi by Immuneel Therapeutics represents a monumental stride in India's fight against cancer. As the nation’s first global CAR T-cell therapy, Qartemi brings hope to patients battling relapsed or refractory Non-Hodgkin Lymphoma, offering an advanced, personalized solution that meets international standards.

Backed by rigorous clinical trials and partnerships with top healthcare institutions, this therapy is poised to address the growing burden of blood cancers in India.

Immuneel’s commitment to affordability, indigenous manufacturing, and innovation ensures that world-class treatments are no longer out of reach for Indian patients. With Qartemi, Immuneel not only revolutionizes the cancer immunotherapy landscape but also underscores India’s potential as a global leader in next-generation precision medicine.

This breakthrough is more than just a medical advancement—it is a beacon of hope for countless families, reaffirming that the future of cancer care is both accessible and transformative.